Assessing Imaging Response to Therapy - 31/08/15

Doi : 10.1016/j.rcl.2015.05.010

Jeet Minocha, MD ^a,^⁎ , Robert J. Lewandowski, MD, FSIR ^b
^a Division of Interventional Radiology, Department of Radiology, University of California San Diego, 200 West Arbor Drive, #8756, San Diego, CA 92103-8756, USA
^b Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, 676 North Saint Clair Street, Suite 800, Chicago, IL 60611, USA

^∗Corresponding author.

Résumé

Locoregional therapies (LRTs) have proved valuable in the treatment of patients with cancer, most commonly in the liver. Accurate assessment of response to these therapies is crucial because objective response can be a surrogate of improved survival. Imaging plays an essential role in the objective evaluation of tumor response to most cancer therapies, including LRTs. Assessing imaging response to LRTs, however, can be challenging and is evolving. This article reviews the different criteria used to assess radiologic response to LRTs, with special attention to imaging assessment following treatment of hepatocellular carcinoma.

Le texte complet de cet article est disponible en PDF.

Keywords : World Health Organization (WHO), Response evaluation criteria in solid tumors (RECIST), European Association for the Study of the Liver (EASL), Modified RECIST (mRECIST), Response assessment, Computed tomography (CT), MR imaging